These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36682470)

  • 21. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
    Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
    Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
    Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
    Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
    Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatic veno-occlusive disease following sirolimus-based immune suppression.
    Khimani F; McDonald GB; Shulman HM; Betts B; Locke F; Fernandez H; Anasetti C; Pidala J
    Bone Marrow Transplant; 2019 Jan; 54(1):85-89. PubMed ID: 29895929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
    Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
    Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
    Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
    Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Marks DI; Kebriaei P; Stelljes M; Gökbuget N; Kantarjian H; Advani AS; Merchant A; Stock W; Cassaday RD; Wang T; Zhang H; Loberiza F; Vandendries E; DeAngelo DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1720-1729. PubMed ID: 31039409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and
    Kayser S; Sartor C; Luskin MR; Webster J; Giglio F; Panitz N; Brunner AM; Fante M; Lutz C; Wolff D; Ho AD; Levis MJ; Schlenk RF; Papayannidis C
    Haematologica; 2022 Sep; 107(9):2064-2071. PubMed ID: 35142153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.
    Richardson PG; Smith AR; Kernan NA; Lehmann L; Ryan RJ; Grupp SA
    Transplant Cell Ther; 2021 Jan; 27(1):88.e1-88.e6. PubMed ID: 32950693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
    Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
    N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
    Badar T; Szabo A; Wadleigh M; Liedtke M; Arslan S; Siebenaller C; Aldoss I; Schultz E; Hefazi M; Litzow MR; Kuo E; Wang A; Curran E; Shallis RM; Podoltsev N; Balasubramanian S; Yang J; Mattison R; Burkart M; Dinner S; Advani A; Atallah E
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):556-560.e2. PubMed ID: 32291234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.
    Mohty M; Blaise D; Peffault de Latour R; Labopin M; Bourhis JH; Bruno B; Ceballos P; Detrait M; Gandemer V; Huynh A; Izadifar-Legrand F; Jubert C; Labussière-Wallet H; Lebon D; Maury S; Paillard C; Pochon C; Renard C; Rialland F; Schneider P; Sirvent A; Asubonteng K; Guindeuil G; Yakoub-Agha I; Dalle JH
    Bone Marrow Transplant; 2023 Apr; 58(4):367-376. PubMed ID: 36564486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
    Jabbour E; Short NJ; Senapati J; Jain N; Huang X; Daver N; DiNardo CD; Pemmaraju N; Wierda W; Garcia-Manero G; Montalban Bravo G; Sasaki K; Kadia TM; Khoury J; Wang SA; Haddad FG; Jacob J; Garris R; Ravandi F; Kantarjian HM
    Lancet Haematol; 2023 Jun; 10(6):e433-e444. PubMed ID: 37187201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
    Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
    Corbacioglu S; Jabbour EJ; Mohty M
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1271-1280. PubMed ID: 30797942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
    Mavrikou I; Chatzidimitriou D; Skoura L; Nikolousis E; Sakellari I; Gavriilaki E
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
    Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
    Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
    Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
    Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.